John Holland
PARADISE VALLEY, AZ (USA)
Role(s):
C-Level Executive (CEO, CFO, etc.)
Life Metrics, LLC
Find More Startups
Startup
Location:
Paradise Valley
Industry:
Bio-Technology
Year Founded:
2013
Number Employees:
1-10 people
Business Stage:
Creation/Idea
Entity Type:
Limited Liability Company
Description:
The answer can be found in one drop of your blood. Introducing BioSpan. Intelligent Life Management.
Executive Synopsis
There is a problem in financial markets that is potentially bigger than the housing bust, student loan debt and derivatives, combined: Longevity risk. BioSpan was conceived to mitigate that risk before it develops into the next international crisis.
BioSpan is a blood test that will be developed from paradigm-shattering research proposed by Life Metrics, LLC. The research team is headed by globally-recognized epidemiologists Dr. Albert Hofman formerly from the Erasmus Clinic in the Netherlands, now chair of department of epidemiology at the Harvard Medical Hospital using clinical records and blood samples from the world’s pre-eminent cohort study of degenerative diseases in the elderly— the Rotterdam Study—and the protein analyses of the samples are being done by a U.S. company that leads the world in large-scale protein identification using minimal sera quantities (±60 μl).
The proposed research is large-scale, predictively valid and the sera content consistency will render findings statistically conclusive and reproducible. As such, this research into the lifespan predictive value of proteins is not just the first serious piece of work done in this area, it is one of the boldest studies ever undertaken in the field of proteomics.
The application of the research findings will be aimed at addressing longevity risk markets: financial, insurance and pension planning. There is already a (confusing) glut of “one off” predictive studies aimed at specific individual diseases and designed for use in diagnostic markets. The objective of Life Metric’s research is to discover an “all cause” mortality signature in an individual’s blood proteins that will, in conjunction with other biometric and demographic data, yield an individual estimate of lifespan expressed in number of months remaining